Press Releases Pfizer Inc.

Stocks

PFE

US7170811035

Pharmaceuticals

Market Closed - NYSE Other stock markets 04:02:50 2026-07-16 pm EDT			After hours 08:00:00 pm
25.14 ^USD	+1.29%		24.56	-2.29%

03:01am	A Tough Week for the Market's Favourite Stocks
Jul. 16	Pfizer suspends sales of Premarin vaginal cream in India, citing supply challenges	RE

Press Releases

Jul. 16	AM Best Affirms Credit Ratings of Blue Whale Re Ltd	AQ
Jul. 13	“2” Does Not Provide Written Description Support For “1”: Federal Circuit Affirms District Court’s Invalidation Of Patent	AQ
Jul. 10	Pfizer : U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin EligibilityPrescription MedicinesMedicines	PU
Jul. 10	U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility	BU
Jul. 06	“A One-Carbon Poison Pill”: Enanta v. Pfizer And The “Typo” That Lost A Priority Date	AQ
Jun. 24	Pfizer Declares Third-Quarter 2026 Dividend	BU
Jun. 24	Pfizer : FDA Approves Pfizer’s IBRANCE Regimen for HR , HER2 Metastatic Breast Cancer Frontline Maintenance	PU
Jun. 24	FDA Approves Pfizer’s IBRANCE Regimen for HR+, HER2+ Metastatic Breast Cancer Frontline Maintenance	BU
Jun. 23	Pfizer Invites Public to View and Listen to Webcast of August 4 Conference Call with Analysts	BU
Jun. 22	Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer	BU
Jun. 18	Pfizer Announces Chief Financial Officer Transition	BU
Jun. 08	U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need	BU
Jun. 06	Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer’s GLP-1 RA Berobenatide	BU
Jun. 01	Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference	BU
May. 31	Pfizer : BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer	PU
May. 31	Pfizer’s BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer	BU
May. 30	TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancer	BU
May. 29	Pfizer : European Commission Authorizes Update to Pediatric Use of Pfizer and BioNTech COVID 19 Vaccine	PU
May. 29	Seven-Year Analysis from Pfizer’s LORBRENA CROWN Trial Shows Longest Progression-Free Survival Reported to Date in Advanced Non-Small Cell Lung Cancer	BU
May. 28	Pfizer and Innovent Biologics Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines	BU
May. 27	Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference	BU
May. 20	Pfizer Advances Pivotal Pediatric Pneumococcal Vaccine Program Following Strong Positive Phase 2 Results	BU
May. 13	European Commission Approves Pfizer’s HYMPAVZI for the Treatment of Adults and Adolescents with Hemophilia A or B With Inhibitors	BU
May. 12	Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)	AQ
May. 05	Pfizer : First Quarter 2026 Transcript	PU